Gold Prices Rise on QE3 Talk

Source: The Street. Andrea Tse (12/6/10)

"Federal Reserve Chairman Ben Bernanke said the Fed would consider expanding QE."

Gold prices were planted in positive territory Monday morning as Federal Reserve chairman Ben Bernanke said that the Fed would consider expanding its quantitative easing program.

In an interview with CBS' 60 Minutes over the weekend, Bernanke signaled that the central bank could expand its $600 billion bond purchase program to address the high unemployment rate.

This announcement, coupled with ongoing uncertainty about the Euro-zone's ability to contain its debt crisis, helped keep gold futures in positive territory. The rise was kept in check with a stronger dollar and stocks. According to the Associated Press, Bernanke said he hopes the Fed's bond buying will lower bond yields and encourage investment in stocks—boosting business activity and economic growth in the country.

Gold for February delivery rose $6.30 to $1,412.50 an ounce at the Comex division of the New York Mercantile Exchange. The gold price has traded as high as $1,420 and as low as $1,409.80 before the market open Monday.

The U.S. dollar index was rising 0.7% to $79.92 while the euro fell 1.2% to $1.33 versus the dollar. The spot gold price was lower by $1.60, according to Kitco's gold index.

According to AP, Bernanke said fears that the Fed would be printing more money and taking inflation risks through its bond purchases was a "myth." He said the Fed isn't printing money when buying Treasuries and the purchase won't result in a significant expansion of money circulating in the market, AP reported.

Gold prices approached new highs Friday, driven by a particularly disappointing November U.S. unemployment report. The unemployment rate rose to 9.8%, the loftiest level since April. All the results were greatly below expectations.

Silver prices were adding $0.37 to $29.65 while copper was flat at about $3.99.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.